Clinical trial · Observational
Postmarketing Study of Empliciti in Korean Patients With Multiple Myeloma
Empliciti (Elotuzumab) Postmarketing Surveillance in Korean Patients With Multiple Myeloma
NCT03660072CI-TRIAL-00058759withdrawnClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Business objectives have changed
Summary
Brief summary (as posted)
This study is a regulatory postmarketing surveillance study for Empliciti with a representative sample of the overall Korean multiple myeloma (MM) population.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Non-Interventional | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Empliciti combination therapy
- description
- Adult patients with a confirmed diagnosis of MM who have received, are currently receiving, or will begin Empliciti combination therapy
- interventionNames
- Other: Non-Interventional
Primary outcomes (1)
- measure
- Incidence of AE's and SAE's
- timeFrame
- 24 Months
Secondary outcomes (2)
- measure
- Overall response of Empliciti treatment with lenalidomide and dexamethasone
- timeFrame
- 24 Months
- measure
- Incidence of infusion-related reactions associated with Empliciti treatment in combination with lenalidomide and dexamethasone
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 19 Years
Show eligibility criteria text
Inclusion Criteria: * Adult participants who have a confirmed diagnosis of Multiple Myeloma (MM) Exclusion Criteria: * Participants who use Empliciti for therapeutic indications which are not approved for Empliciti combination therapy in Korea * Patients in whom treatment with Empliciti (as clarified in the Korean label) is contraindicated Other protocol defined inclusion/exclusion criteria could apply
References
Publications (0)
Data not yet available
No reference posted for this study.